References
- Sidossis L, Kajimura S. Brown and beige fat in humans: thermogenic adipocytes that control energy and glucose homeostasis. J Clin Investig. 2015;125(2):478–486.
- Kharitonenkov A, DiMarchi R. FGF21 revolutions: recent advances illuminating FGF21 biology and medicinal properties. Trends Endocrinol Metabol. 2015;26(11):608–617.
- Heppner KM, Habegger KM, Day J, et al. Glucagon regulation of energy metabolism. Physiol Behav. 2010;100(5):545–548.
- Unger RH, Roth MG. A new biology of diabetes revealed by Leptin. Cell Metab. 2015;21(1):15–20.
- Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114(11):1788–1803.
- Sohn J-W, Elmquist JK, Williams KW. Neuronal circuits that regulate feeding behavior and metabolism. Trends Neurosci. 2013;36(9):504–512.
- Aydin S, Kuloglu T, Aydin S. Copeptin, adropin and irisin concentrations in breast milk and plasma of healthy women and those with gestational diabetes mellitus. Peptides. 2013;47:66–70.
- Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8(6):468–481.
- St-Onge M-P, Shechter A, Shlisky J, et al. Fasting plasma adropin concentrations correlate with fat consumption in human females. Obesity (Silver Spring). 2014;22(4):1056–1063.
- Gao S, McMillan RP, Zhu Q, et al. Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab. 2015;4(4):310–324.
- Akcilar R, Kocak FE, Simsek H, et al. Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats. Bratisl Lek Listy. 2016;117(2):100–105.
- Lian A, Wu K, Liu T, et al. Adropin induction of lipoprotein lipase expression in tilapia hepatocytes. J Mol Endocrinol. 2016;56(1):11–22.
- Ganesh Kumar K, Zhang J, Gao S, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring). 2012;20(7):1394–1402.
- Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005;307(5708):384–387.
- Gao S, McMillan RP, Jacas J, et al. Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes. 2014;63(10):3242–3252.
- Muoio DM. Metabolic inflexibility: when mitochondrial indecision leads to metabolic gridlock. Cell. 2014;159(6):1253–1262.
- Wu P, Inskeep K, Bowker-Kinley MM, et al. Mechanism responsible for inactivation of skeletal muscle pyruvate dehydrogenase complex in starvation and diabetes. Diabetes. 1999;48(8):1593–1599.
- Wong C-M, Wang Y, Lee JTH, et al. Adropin is a brain membrane-bound protein regulating physical activity via the NB-3/Notch signaling pathway in mice. J Biol Chem. 2014;289(37):25976–25986.
- Butler AA, Tam CS, Stanhope KL, et al. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab. 2012;97(10):3783–3791.
- Butler AA, St-Onge M-P, Siebert EA, et al. Differential responses of plasma adropin concentrations to dietary glucose or fructose consumption in humans. Sci Rep. 2015;5:14691.
- Bremer AA, Stanhope KL, Graham JL, et al. Fish oil supplementation ameliorates fructose-induced hypertriglyceridemia and insulin resistance in adult male rhesus macaques. J Nutr. 2014;144(1):5–11.
- Aydin S. A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. Peptides. 2015;72:4–15.
- Jedrychowski MP, Wrann CD, Paulo JA, et al. Detection and quantitation of circulating human Irisin by tandem mass spectrometry. Cell Metab. 2015;22(4):734–740.
- Tschop MH, Speakman JR, Arch JRS, et al. A guide to analysis of mouse energy metabolism. Nat Methods. 2011;9(1):57–63.
- Lovren F, Pan Y, Quan A, et al. Adropin is a novel regulator of endothelial function. Circulation. 2010;122(11 Suppl):S185–92.